[go: up one dir, main page]

Chen et al., 2024 - Google Patents

Discovery of Novel Anti‐Resistance AR Antagonists Guided by Funnel Metadynamics Simulation

Chen et al., 2024

View PDF @Full View
Document ID
9092667749270795824
Author
Chen H
Zhou Y
Wang X
Chai X
Wang Z
Wang E
Xu L
Hou T
Li D
Duan M
Publication year
Publication venue
Advanced Science

External Links

Snippet

Androgen receptor (AR) antagonists are widely used for the treatment of prostate cancer (PCa), but their therapeutic efficacy is usually compromised by the rapid emergence of drug resistance. However, the lack of the detailed interaction between AR and its antagonists …
Continue reading at advanced.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/70—Chemoinformatics, i.e. data processing methods or systems for the retrieval, analysis, visualisation, or storage of physicochemical or structural data of chemical compounds
    • G06F19/706—Chemoinformatics, i.e. data processing methods or systems for the retrieval, analysis, visualisation, or storage of physicochemical or structural data of chemical compounds for drug design with the emphasis on a therapeutic agent, e.g. ligand-biological target interactions, pharmacophore generation
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/16—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for molecular structure, e.g. structure alignment, structural or functional relations, protein folding, domain topologies, drug targeting using structure data, involving two-dimensional or three-dimensional structures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/12—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for modelling or simulation in systems biology, e.g. probabilistic or dynamic models, gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/28—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions

Similar Documents

Publication Publication Date Title
Xu et al. Discovery of CREBBP bromodomain inhibitors by high-throughput docking and hit optimization guided by molecular dynamics
Biebl et al. Structural elements in the flexible tail of the co-chaperone p23 coordinate client binding and progression of the Hsp90 chaperone cycle
Mishra et al. Systematic mutant analyses elucidate general and client-specific aspects of Hsp90 function
Vuorinen et al. Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17β-hydroxysteroid dehydrogenase 2 inhibitors
Boulton et al. Mechanism of selective enzyme inhibition through uncompetitive regulation of an allosteric agonist
Chen et al. Discovery of Novel Anti‐Resistance AR Antagonists Guided by Funnel Metadynamics Simulation
Xing et al. Machine-learning-assisted approach for discovering novel inhibitors targeting bromodomain-containing protein 4
US9198891B2 (en) Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase
Bennetts et al. Inhibition of skeletal muscle ClC-1 chloride channels by low intracellular pH and ATP
Krishna et al. Pharmacophore-based screening and identification of novel human ligase I inhibitors with potential anticancer activity
Zhao et al. HIFs: New arginine mimic inhibitors of the Hv1 channel with improved VSD–ligand interactions
Hajduk et al. Ligand binding to domain-3 of human serum albumin: a chemometric analysis
Bernetti et al. Binding residence time through scaled molecular dynamics: A prospective application to hDAAO inhibitors
Shah et al. In silico identification of a β2-adrenoceptor allosteric site that selectively augments canonical β2AR-Gs signaling and function
Ippolito et al. Identification of a β-arrestin-biased negative allosteric modulator for the β2-adrenergic receptor
Diouf et al. Alteration of RNA splicing by small-molecule inhibitors of the interaction between NHP2L1 and U4
La Sala et al. Unraveling the allosteric cross-talk between the coactivator peptide and the ligand-binding site in the glucocorticoid receptor
Chen et al. Mapping temperature-dependent conformational change in the voltage-sensing domain of an engineered heat-activated K+ channel
Gomez-Gutierrez et al. Identification of potential small molecule binding pockets in p38α MAP kinase
Gagné et al. Network of long‐range concerted chemical shift displacements upon ligand binding to human angiogenin
Guo et al. Systematic prediction of familial hypercholesterolemia caused by low-density lipoprotein receptor missense mutations
Aliakbar Tehrani et al. Molecular dynamics simulations provide structural insight into binding of cyclic dinucleotides to human STING protein
Xu et al. Molecular mechanisms of the blockage of glioblastoma motility
Laudadio et al. Mechanistic insight toward EGFR activation induced by ATP: role of mutations and water in ATP binding patterns
Sun et al. Scaffold hopping and optimization of small molecule soluble adenyl cyclase inhibitors led by free energy perturbation